LDN-212854

LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC50: 1.3 nM) . LDN-212854 also inhibits ALK1 (IC50: 2.40 nM) . LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC) [1][2].

Product Specifications

CAS Number

[1432597-26-6]

UNSPSC

12352005

Hazard Statement

H301

Target

TGF-β Receptor

Type

Reference compound

Related Pathways

TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/LDN-212854.html

Concentration

10mM

Purity

99.70

Solubility

DMSO : ≥ 30 mg/mL

Smiles

C12=C(C3=C4N=CC(C5=CC=C(N6CCNCC6)C=C5)=CN4N=C3)C=CC=C1N=CC=C2

Molecular Formula

C25H22N6

Molecular Weight

406.48

Precautions

H301

References & Citations

[1]Mohedas AH, et al. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol. 2013;8 (6) :1291-302.|[2]Han Chen, et al. BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinoma. Mol Oncol. 2021 Aug;15 (8) :2203-2218.